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Many patients with non-dialysis dependent chronic kidney
disease (CKD) live far from the closest nephrologist; although
reversible, this might constitute a barrier to optimal care. In
order to evaluate outcomes, we selected 31,452 outpatients
older than 18 years with an estimated glomerular filtration
rate (eGFR) less than 45ml/min per 1.73m2 who had serum
creatinine measured at least once during 2005 in Alberta,
Canada. We then used logistic regression to examine the
association between outcomes of 6545 patients who lived
more than 50km from the nearest nephrologist. Over a
median follow-up of 27 months, 7684 participants died and
15,075 were hospitalized at least once. Compared with those
living within 50km, those further away were significantly less
likely to visit a nephrologist or a multidisciplinary CKD clinic
within 18 months of the index measurement of the eGFR.
Similarly, remote dwellers with diabetes were significantly
less likely to have hemoglobin A1c evaluated within 1 year of
the index eGFR measurement, to have urinary albumin
assessed biannually, or to receive an angiotensin converting
enzyme inhibitor or receptor blocker in the setting of
diabetes or proteinuria. Remote-dwelling participants were
also significantly more likely to die or be hospitalized during
follow-up than those living closer. Thus, among people with
CKD, remote dwellers were less likely to receive specialist
care, recommended laboratory testing, and appropriate
medications, and were more likely to die or be hospitalized
compared with those living closer to a nephrologist.
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Chronic kidney disease (CKD) is an important public health
problem associated with accelerated cardiovascular disease
and increased mortality.1 Two recent Canadian studies
suggested that mortality was higher among remote-dwelling
hemodialysis and peritoneal dialysis patients.2,3 Previous
studies have shown that remote/rural dwelling patients with
other (non-renal) conditions are not as likely to receive
effective preventive therapies.4,5 This raises the possibility
that the excess mortality in remote-dwelling dialysis patients
may be because of documented gaps between recommended
practice and real world care.6–9 This issue is especially
germane for Canadian provinces where rural/remote resi-
dence is common and specialists are often located only in
larger centers.
It is unknown whether remote-dwelling patients with
non-dialysis dependent CKD have worse clinical outcomes,
and whether they are less likely to receive preventive therapies
to manage kidney disease and its complications, such as
atherosclerosis. As timely and appropriate treatment for CKD
is known to reduce morbidity, mortality, and progression to
kidney failure10–15 correcting such gaps in care would be
expected to result in better clinical outcomes and might
reduce health care costs.
We studied a large cohort of people with CKD in a single
Canadian province and examined the relation between
residence location and markers of good quality care including
access to specialty care and adherence to clinical practice
guidelines, including the use of relevant laboratory testing
and appropriate medications. We also considered whether the
risk of clinically relevant outcomes was increased among
remote dwellers.
RESULTS
Figure 1 shows participant flow. Figure 2 shows the density of
people with estimated glomerular filtration rate (eGFR)
o45 ml/min per 1.73 m2 in Alberta in relation to available
nephrologists or internists. Characteristics of the 31,452
participants by distance to the closest nephrologist are shown
in Table 1; 79% lived within 50 km of a nephrologist and
so were considered urban dwellers. The remaining 21%
or ig ina l a r t i c l e http://www.kidney-international.org
& 2011 International Society of Nephrology
Received 21 May 2010; revised 10 July 2010; accepted 27 July 2010;
published online 6 October 2010
Correspondence: Marcello Tonelli, 7-129 Clinical Science Building, 8440 112
Street, Edmonton, Alberta, Canada T6B 2G3.
E-mail: mtonelli-admin@med.ualberta.ca
210 Kidney International (2011) 79, 210–217
of participants were classified as remote dwellers. As shown
in Table 1, remote dwellers were younger, more likely to be of
aboriginal race, and more frequently received financial
subsidy/assistance. Remote dwellers also carried a higher
burden of comorbidities such as heart failure, chronic
obstructive pulmonary disease, diabetes and peripheral
vascular disease, and tended to have more severely impaired
kidney function.
A similar proportion of participants in every distance
category had at least one visit to a primary care practitioner
within 18 months following the index eGFR (99.8, 99.8, 99.9,
and 99.4% for 0–50, 50.1–100, 100.1–200, and 4200 km
respectively).
Table 2 shows the likelihood of a nephrologist visit within
18 months following the index eGFR by distance category.
Remote dwellers were significantly less likely to visit a
nephrologist or a multidisciplinary CKD clinic within 18
months of the index eGFR, as compared with those living
closer to a nephrologist (Po0.0001). Compared with urban
dwellers, patients living 4200 km from the closest nephrol-
ogist had odds of 0.34 (95% confidence interval (95% CI)
0.2, 0.57) for a nephrologist visit. Results were similar when
the more liberal definition of specialist visit (including
general internists as well as nephrologists and multidisci-
plinary clinics) was considered. When we further relaxed the
definition of specialist visit to include visits to a nephrologist
or multidisciplinary CKD at any time during follow-up,
results again showed that remote dwellers were significantly
less likely to receive specialist care (Po0.0001).
Table 3 summarizes process-based outcome markers for
good quality care in patients with CKD, by distance category.
There was a significant trend for decreased likelihood of
annual hemoglobin A1c (HbA1C) measurement for partici-
pants with diabetes across distance categories (Po0.0001).
Compared with participants with diabetes who livedo50 km
from the closest nephrologists, those that lived 4200 km
were less likely (odds ratio (OR) 0.43; 95% CI 0.27, 0.70) to
have A1c measured annually. Remote dwellers were also
less likely to have urinary albumin assessed within 6 months
of index eGFR o45 ml/min per 1.73 m2 (Po0.0001), and to
receive an angiotensin-converting enzyme inhibitor (ACEI)
or angiotensin receptor blocker (ARB) in the setting of
diabetes or proteinuria). Although appropriate statin
use was also significantly less likely in remote dwellers
(Po0.007), a clinically relevant decrease in the likelihood of
statin use was only observed in those living 100–200 km from
the closest nephrologist (0.78, 95% CI 0.63, 0.97).
During median follow-up of 27 months, 7684 (24%) of
participants died, and 15075 (48%) were hospitalized at least
once. Remote-dwelling participants were significantly more
likely to die (Po0.0001) or to be hospitalized (Po0.0001)
than those living closer (Table 4). Median length of stay
among those hospitalized was also significantly longer among
remote dwellers, than in those living closer to a nephrologist
(Table 4). The likelihood of the composite renal outcome
(end-stage renal disease (ESRD) or doubling of serum
creatinine) did not vary between urban and remote dwellers
(P¼ 0.21; Table 4).
Results were similar when eGFR o30 ml/min per 1.73 m2
was used as the threshold for appropriate referral to a
nephrologist. Compared with those living within 50 km of
the closest nephrologist, the OR among those living
4200 km away were 0.24 (0.13, 0.44), 0.49 (0.27, 0.90),
0.78 (0.42, 1.45), and 1.23 (0.81, 1.88) for the likelihood of
nephrologist visit, annual HbA1C measurement, assessment
of urinary albumin, and statin prescription respectively. The
relative rate of mortality (OR 1.20; 95% CI 1.01, 1.44), the
OR of any hospitalization (OR 1.55; 95% CI 1.29, 1.87), and
the median number of hospital days (seven versus five,
Po0.0001) were also significantly higher in those living
4200 km from the closest nephrologist, compared with the
referent group—but not the likelihood of ACEI or ARB
prescription (OR 1.23; 95% CI 0.69, 2.22).
Results were similar in the other sensitivity analyses
described in the methods. Specifically, remote dwellers
remained less likely to receive specialist care, to undergo
assessment of HbA1C and proteinuria, and to receive an
ACEI or ARB in the setting of proteinuria—but were more
likely to die or be hospitalized.
DISCUSSION
In Alberta nearly one in five patients with non-dialysis
dependent CKD lives further than 50 km from the closest
nephrologist. Our findings demonstrate that the further such
patients live from an urban center, the less likely they are
to visit a specialist or specialty clinic for evaluation. Given
the complexity of managing CKD, this decreased contact
with specialists may have resulted in the lower likelihood of
Total population in 2005
cohort = 790,861
Postal code is missing or not in Alberta = 29
Postal code is incorrect = 15
Effective study population = 790,817
Effective study population with index 
eGFR <45 = 31,452
Patients with index eGFR <45 = 33,045
Patients with ESRD after index data = 1175
Patients with ESRD receiving dialysis or 
transplant before index data = 1593
Figure 1 | Study flow. Abbreviations: eGFR, estimated glomerular
filtration rate; ESRD, end-stage renal disease.
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markers of good quality care (measurement of HbA1c and
urinary albumin in diabetics and initiating ACE or ARB
treatment) also observed with increasing remoteness. Lack of
specialist involvement and these different patterns of care
may also have contributed to the increased risk of mortality
and hospital admission that we observed among remote
dwellers, compared with those living closer. Results were
similar using two different eGFR thresholds to define criteria
for referral, and in several sensitivity analyses—increasing
confidence that the findings are robust.
Why was residing further from the closest nephrologist
associated with worse process-based and clinical outcomes
among people with identified CKD? The simplest explana-
tion is that nephrologists and internists are predominantly
located in major centers (Figure 2). Thus, remote-dwelling
patients might decline referrals to urban specialists as the
associated travel may pose financial and logistical difficulties.
Alternatively, primary care physicians may have a higher
threshold for referral of remote dwellers to urban physicians
for similar reasons. We speculate that these patient- and
physician-related barriers to specialist referral led to the
decreased use of measured characteristics of good quality care
(and perhaps to decreased use of other beneficial treatments
that we were unable to quantify), which in turn led to the
excess mortality and risk of hospitalization observed in our
study. Why remote residence location was not also associated
with higher risk of dialysis treatment is unclear, but may
relate to survivorship bias, a lower likelihood of agreeing to
initiate dialysis among remote dwellers, or perhaps reduced
statistical power for this less frequent outcome.
Previous studies have examined remote-urban health
differences in various aspects of CKD care with mixed
results. Studies from North America have shown that in
terms of renal transplantation, remote dwellers have no
disadvantage,2 and waiting times may even be shorter for
those living further away.16 However, in CKD patients




Density of people 
with eGFR<45 ml/




Figure 2 | Location of specialist physicians and people with chronic kidney disease in the province of Alberta. eGFR, estimated
glomerular filtration rate.
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Table 1 | Demographic and clinical characteristics by geographical distance from the closest nephrologist










Age, mean (s.d.), years 76.0 (12.5) 75.5 (12.3) 76.9 (11.9) 73.7 (13.5) o0.0001
Female 15,987 (64) 1460 (64) 1368 (63) 1292 (60) 0.0006
Aboriginal status 175 (1) 118 (5) 39 (2) 126 (6) o0.0001
Index eGFR 35.2 (8.5) 34.3 (9.1) 34.4 (8.8) 34.2 (9.3) o0.0001
eGFR stages
o15 868 (3) 104 (5) 83 (4) 117 (5) o0.0001
15–29.9 4783 (19) 493 (22) 502 (23) 458 (21) —
30–44.9 19,256 (77) 1617 (73) 1584 (73) 1587 (73) —
—
Comorbidities
Cancer 3466 (14) 307 (14) 327 (15) 297 (14) 0.497
Cardiovascular disease 3368 (14) 285 (13) 316 (15) 290 (13) 0.417
Heart failure 6147 (25) 667 (30) 735 (34) 655 (30) o0.0001
COPD 6505 (26) 598 (27) 703 (32) 725 (34) o0.0001
Dementia 2820 (11) 256 (12) 252 (12) 199 (9) 0.021
Diabetes mellitus 5151 (21) 537 (24) 495 (23) 581 (27) o0.0001
HIV 8 (0.03) 2 (0.09) 0 (0) 0 (0) 0.216a
Metastatic cancer 535 (2) 71 (3) 51 (2) 57 (3) 0.008
Myocardial infarction 3505 (14) 298 (13) 269 (12) 309 (14) 0.152
Mild liver disease 520 (2) 46 (2) 34 (2) 64 (3) 0.013
Moderate/severe liver disease 155 (1) 15 (1) 14 (1) 22 (1) 0.187
Paraplegia 428 (2) 27 (1) 37 (1) 36 (2) 0.380
Peptic ulcer disease 1219 (5) 134 (6) 101 (5) 101 (5) 0.084
Peripheral vascular disease 2820 (11) 204 (9) 201 (9) 241 (11) 0.001
Rheumatological disease 1062 (4) 118 (5) 90 (4) 96 (4) 0.121
Incomeb
Below poverty line 2354 (9) 424 (19) 256 (12) 194 (10) o0.0001
Between poverty line and Alberta median income 12,356 (50) 1529 (70) 1680 (78) 1063 (53) —
Higher than median 10,143 (41) 233 (11) 219 (10) 762 (38) —
Abbreviations: COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus.
aExact test.
bMedian income was unavailable for 239 participants. The Alberta median individual employment income was $29,500/year in 2005. The poverty line is $14,914/year for rural
areas, $18,659/year for urban areas (except Calgary and Edmonton), and $21,666/year for Calgary and Edmonton.
Values are n (%) or mean (s.d.) as appropriate.
Table 2 | Likelihood of timely specialist referral by distance from the closest nephrologist
0–50 km 50.1–100 km 100.1–200 km 4200 km
Referral to nephrologist or CKD multidisciplinary clinic, within 18 monthsa of index eGFRb
People (no.) 24,853 2186 2155 2019
Events (no.) 10,000 626 585 496
Adjusted OR (95% CI) 1 0.56 (0.47, 0.68) 0.53 (0.41, 0.68) 0.34 (0.20, 0.57)
P for trend o0.0001
Referral to nephrologist, CKD multidisciplinary clinic, or general internist, within 18 months of index eGFRa
People (no.) 24,853 2186 2155 2019
Events (no.) 15,630 1099 938 936
Adjusted OR (95% CI) 1 0.53 (0.50, 0.58) 0.38 (0.28, 0.52) 0.37 (0.27, 0.50)
P for trend o0.0001
Any referral to a nephrologist or CKD multidisciplinary clinic without a time constraintb
People (no.) 24,853 2186 2155 2019
Events (no.) 18,557 1423 1345 1078
Adjusted OR (95% CI) 1 0.63 (0.41, 0.96) 0.56 (0.42, 0.75) 0.28 (0.16,0.5)
P for trend o0.0001
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; LDL, low-density lipoprotein; OR, odds ratio.
aMeasurement in relation to index eGFRo45ml/min per 1.73m2.
bSensitivity analysis in which any referral to nephrologists or CKD clinic was considered acceptable.
Adjusted for age, index eGFR, gender, income, aboriginal race, diabetic status, and all comorbidities noted in Table 1.
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receiving hemodialysis, remote dwellers had higher rates of
mortality, particularly from infectious causes.17 In a large
cohort of people residing in South Carolina, higher ESRD
incidence was observed with those living in rural areas, with
higher physician density having a protective effect on the
incidence of ESRD.18 In Queensland (Australia), higher
mortality from renal causes was observed in indigenous
people, and this disparity increased with increasingly remote
residence locations.19
Our study has several limitations. First, we excluded
people without a valid postal code, although this accounted
for o2% of the effective study population. Second, the
Table 3 | Likelihood of process-based outcomes, by distance from the closest nephrologist
0–50 km 50.1–100 km 100.1–200 km 4200 km
Glycosylated hemoglobin (A1C) tested annually for diabetic patients
People (no.) 7715 747 703 708
Events (no.) 4068 337 267 256
Adjusted OR (95% CI) 1 0.73 (0.57, 0.93) 0.58 (0.35, 0.95) 0.43 (0.27, 0.7)
P for trend o0.0001
Urinary albumin measureda
People (no.) 24,853 2186 2155 2019
Events (no.) 16,243 1141 1070 1119
Adjusted OR (95% CI) 1 0.58 (0.41,0.81) 0.54 (0.37,0.79) 0.62 (0.36, 1.1)
P for trend o0.0001
ACEI or ARB use among participants aged 466 with diabetes or significant proteinuriaa
People (no.) 6297 605 580 509
Events (no.) 4928 448 441 371
Adjusted OR (95% CI) 1 0.81 (0.64, 1.03) 0.93 (0.72, 1.20) 0.75 (0.63, 0.89)
P for trend 0.0003
Statin use among participants aged 466 with LDL 42.5mmol/la
People (no.) 6195 447 464 395
Events (no.) 2671 204 172 169
Adjusted OR (95% CI) 1 1 (0.80, 1.30) 0.78 (0.63, 0.97) 0.98 (0.64, 1.50)
P for trend 0.007
Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CI, confidence interval; CKD chronic kidney disease; eGFR, estimated
glomerular filtration rate; LDL, low-density lipoprotein; OR, odds ratio.
aMeasurement within 6 months of index eGFRo45ml/min per 1.73m2.
Adjusted for age, index eGFR, gender, income, aboriginal race, diabetic status, and all comorbidities noted in Table 1.
Table 4 | Clinically relevant outcomes in remote dwelling patients with CKD, by geographic distance from the closest
nephrologist
0–50 km 50.1–100 km 100.1–200 km 4200 km
Hospitalization
People (no.) 24,853 2186 2155 2019
Events (no.) 11,346 1189 1263 1145
Adjusted OR (95% CI) 1 1.3 (1.2, 1.5) 1.5 (1.2, 2.0) 1.5 (1.3, 1.7)
Median length of stay (days) 0 4 4 3
P for trend o0.0001
Mortality
People (no.) 24,907 2214 2169 2162
Events (no.) 5943 557 591 593
Unadjusted rate: per 1000 per year (95% CI) 79.5 (77.8, 81.3) 83.8 (77.8, 89.9) 90.8 (84.5, 97.1) 91.4 (85.2,97.7)
Adjusted relative rate (95% CI) 1 1.03 (0.94,1.13) 1.05 (0.96, 1.14) 1.23 (1.12,1.34)
P for trend o0.0001
P for relative rate trend o0.0001
Composite renal outcome (ESRD or doubling of serum creatinine)
People (no.) 24,701 2160 2117 2129
Events (no.) 2157 198 183 214
Adjusted OR (95% CI) 1 0.82 (0.73,0.93) 0.86 (0.69,1.07) 0.88 (0.7,1.11)
P for trend 0.219
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease; LDL, low-density lipoprotein;
OR, odds ratio.
Adjusted for age, index eGFR, gender, income, aboriginal race, diabetic status, and all comorbidities noted in Table 1.
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classification of residence was based on postal codes available
at the time of the index eGFR measurement. As some
participants may have moved geographic locations during the
study, this may have resulted in misclassification. However, as
patients with higher illness burden are more likely to move
closer to specialist care, updated data on residence location
during follow-up would have been expected to strengthen the
observed observations. Third, calculating distances between
residences and nephrologists necessitated some approxima-
tions. In an attempt to reduce this imprecision we used
relatively broad categories to reduce the risk of bias. Fourth,
we assessed eGFR and proteinuria at a single time point,
which could have introduced misclassification given the
variability in these measures. Finally, although our hypothesis
that remote residence location functions as a geographical
barrier to good quality care is plausible and appealing, the
relationship between health and residential area is complex.
Rural–urban differences are intimately linked to variations in
age, ethnicity, social economic status, and lifestyle as well as
to geographic location.20 Therefore, it is probable that patient
characteristics differed between those living close to and
remote from nephrologists, which may have influenced our
findings. Although we attempted to control for differences in
measured characteristics across distance categories, we
cannot exclude the possibility of residual confounding. In
addition, it is likely that (assuming our hypothesis is correct),
health outcomes and the quality of care are worse for remote
dwellers with other chronic conditions besides CKD.
Potential solutions to overcoming geographic barriers to
good quality CKD care include education of patients and
primary care physicians; enhanced recruitment of specialists
to rural areas; increased use of traveling specialists and/or
mobile multidisciplinary clinics; and more investment in
telehealth technologies. Future studies in this area should aim
to further examine social and structural processes that
influence the delivery of health care in remote geographic
locations.20 Interventions should be aimed at the primary
care level and will need to address education, as prevention
and early intervention is likely needed to improve outcomes
in remote rural dwelling patients.21
In conclusion, our study demonstrates that the likelihood
of timely specialist visits for management of CKD decreases
with increasing remote residence location among patients
treated within a universal healthcare system in Alberta,
Canada. Remote residence location was also associated with
decreased likelihood of good quality CKD care and increasing
risk of mortality and hospitalization. These findings suggest
an opportunity for targeted intervention to improve out-
comes in this population.
METHODS
Setting and participants
Data from the Alberta Kidney Disease Network22 and the
provincial health ministry (Alberta Health and Wellness)
were used for this study. From all outpatients aged418 years
who had serum creatinine measured in Alberta at least once
between 1 January 2005, and 31 December 2005, we selected
those with eGFRo45 ml/min per 1.73 m2, representing
advanced stage 3 CKD. We excluded people with ESRD
receiving dialysis or transplant before their first creatinine
measurement in 2005 (their index date) from analysis
(n¼ 1593). The six-digit postal code for each person’s
residence location at the time of index date was obtained
from the health ministry. Geographic information systems
techniques were used to determine the distance by road (km)
and projected travel time between each person’s home and
the office locations of all nephrologists and internal medicine
specialists (internists) practicing in the province of Alberta.
For each participant, we then determined the distance
by road to the closest nephrologist and to the closest
internist as previously described.17 Distance between each
person’s residence and these facilities was then classified
into the following categories: 0–50, 50.1–100, 100.1–200,
and 4200 km. The median household income for each
postal code was obtained using data from the 2005
Canadian census.
Other measurements
We assessed comorbidity using physician claims and
hospitalization data together with validated algorithms23 for
the variables listed in Table 1. We linked to outpatient
laboratory data for all participants between 1 January 2004 to
31 December 2007, including serum creatinine, low-density
lipoprotein cholesterol, HbA1C, and proteinuria (urinary
albumin:ratio or dipstick urinalysis). In Alberta, medications
are provided free of charge to all residents 465 years of age;
thus we obtained data on drug utilization for ACEI, ARB,
statin and other hypolipidemic agents for such participants.
Outcomes
The primary outcome for this study was all-cause mortality.
All-cause mortality, dates of hospitalization, and the date of
first renal replacement therapy for people who developed
ESRD were determined by linkage to the provincial health
ministry and the provincial renal databases.22 We evaluated
the occurrence of a composite renal outcome: ESRD or
doubling of serum creatinine (as compared with the baseline
value). Markers of good quality care were based on recent
studies and clinical practice guidelines: visit to see a specialist
(within 18 months of an index eGFR measurement o45 ml/
min per 1.73 m2);24 urinary albumin tested at least once
within 6 months following index eGFR o45 ml/min per
1.73 m2;4 glycated hemoglobin tested at least annually during
follow-up for patients with diabetes;25 at least one prescrip-
tion for a statin among patients aged 466 with at least one
low-density lipoprotein value 42.5 mmol/l within 6 months
of index eGFRo45 ml/min per 1.73 m2,13,14 and at least
one prescription for an ACEI or ARB among patients aged
466 years with diabetes or significant proteinuria (defined
by one or more of the following: albumin:creatinine ratio
430 mg/mmol; or protein:creatinine ratio 450 mg/mmol;
or 24 h protein of 4300 mg identified within 6 months
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of index eGFRo45 ml/min per 1.73 m2).10–12,26–29 In effect,
physicians had at least 6 months following the index eGFR
measurement to take action in response to an abnormal
laboratory value. However, we allowed 18 months following
index eGFR for specialist consultation to occur.
In the primary analysis, we considered that a specialist
visit had occurred if the participant had at least one visit to a
nephrologist or multidisciplinary CKD clinic30 (based on
claims to the health ministry). In a secondary analysis, we
considered visits to a nephrologist, a multidisciplinary clinic or
an internist to constitute appropriate referral. Because criteria
for referral to nephrologists are controversial, we performed
a second sensitivity analysis that used an eGFR threshold
of o30 ml/min per 1.73 m2 to define appropriate referral.
Outcomes relating to medication use were restricted to
participants aged X66 years because this group has universal
medication coverage from the provincial drug plan.
Statistical analysis
The baseline demographics and clinic characteristics by
distance were given as mean or proportion. Logistic regression
models were used to identify the association between distance
and markers of good quality care, and to determine the
likelihood of death, hospitalization or kidney failure among
participants in the different distance categories after adjust-
ment for the following potential confounders: age, gender,
index eGFR, previous diabetes, individual health insurance
premium level (a marker of individual-level income), median
neighborhood income, and comorbidity. Adjusted models
were built by using the forward stepwise selection method
using a P-value of 0.05 for removal. Hosmer–Lemeshow
goodness of fit was used to examine the appropriateness of the
fitted models. Mean score and Cochran–Armitage methods
were used to test for trend by distance. To account for
correlation between participants who underwent creatinine
measurement in the same health service region of the province,
we performed all logistic regression models using robust
estimates of variance, defining the cluster (grouping) variable
by each health region. End-of-study date for all analyses was
31 December 2007.
We also performed several sensitivity analyses. First, we
explored the potential effect of misclassification of distance
within a given postal code by testing two extremes: first
assuming that participants resided as close as possible to the
closest nephrologist within their postal code, and second
taking the opposite perspective. Second, in case for which
data were missing, a category of unknown was created and
entered into the model. Third, we reclassified participants
with index eGFRo45 ml/min per 1.73 m2 but subsequent
values X45 ml/min per 1.73 m2 as being free from CKD.
Fourth, to reduce the likelihood that the competing risk of
death influenced findings related to the process-based out-
comes, we repeated analyses after excluding all those that died
within the ascertainment period (6 months following the index
eGFR for all process-based outcomes except specialist referral,
which was 18 months following the index eGFR).
The institutional review boards for the Universities of
Alberta and Calgary approved the study. Analyses were
performed using SAS 9.12 and Stata SE 10.1.
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